Singapore Exchange Limited - Thriving on volatility

27 Apr 2020
  • SGX beat our earnings expectations by 34% for 3Q20.
  • Key business segments saw stellar growth amidst heightened market volatility – FICC grew 23% YoY and Equities grew 31% YoY, contributing to a net profit increase of 38% YoY.
  • SGX maintained a quarterly dividend of 7.5 cents per share in 3Q20.
  • We maintain our NEUTRAL call with a revised TP of S$9.28. We peg our TP to 21.4x P/E, 1 SD below SGX’s 5-year mean. We revise our FY20e earnings forecast upwards by 8% on stellar 3Q20 results as SGX continues to benefit from market volatility as a result of the COVID-19 pandemic.

 

The Positives

+ Derivatives business makes a splash in high volatility environment, raking in S$147.5mn, an increase of 24% YoY from S$119mn a year ago. SGX’s effort in developing its derivatives business was also evident, with non-Asian-hour trading activity contributing to 20% of total derivatives volume, a stark increase from less than 10% of total volume from three years ago.

Currencies and commodities derivatives revenue increased 23% with trading and clearing revenue chalking up S$28.8mn, an improvement of 29% YoY on higher volumes. Currency and commodities futures recorded 14.8mn contracts, an increase of 38% across the same period last year.

Revenue increased 24% from equities derivatives, led by higher trading and clearing revenue of S$65.0mn (+26% YoY from $51.6mn) from a 24% increase in trading volume to 61.5mn contracts (3Q19: 49.5mn contracts). Among which, SGX saw higher interest in Nikkei 225 MSCI Taiwan and Nifty 50 index futures (+85%, +44% and +39% YoY respectively).

 

+ Cash equities business enjoy revitalised interest from dormant retail investors. SGX noted an increase of 50% in accounts that traded in March alone which had no trading activity for the past one year. This propelled a 58% increase in SDAV YoY to S$1.61bn in 3Q20, leading to a 65% increase in trading and clearing revenue to S$67.9mn from S$41.1mn YoY. Settlement and depository management revenue also improved 21% from S$21.4mn to S$25.8mn as a result.

 

+ Consolidation of Scientific Beta contributed to growth in the DCI business, adding S$5.9mn to the segment as DCI revenue grew 26% YoY from S$26.1mn to S$33.0mn.

 

The Negatives

– Equity listing and corporate actions revenue fell 4% YoY on poorer market sentiments. While primary and secondary funds raised in the first three quarters exceeded entire FY19 (primary listing: S$2.2bn vs FY19 of S$1.7bn and secondary listing: S$7.6bn vs FY19 of S$4.7bn), capital-raising activity is expected to slump on weaker market valuations in the current climate.

 

Outlook

The persistence of the COVID-19 will continue to heighten market volatility and benefit SGX’s business. In 3Q20, SGX observed large amounts of funds from institutional investors exiting the market that was matched by fresh funds from retail investors. However, the large amount of fresh funds invested into the bourse is unlikely to be sustainable in subsequent quarters with April’s SDAV standing at around 30% of March’s heightened level.

 

Investment Actions

We maintain our NEUTRAL recommendation with an upward revision of our TP to S$9.28 on a stellar 3Q20 earnings. Our TP is pegged to 21.4x P/E, 1 SD below SGX’s 5-year mean. Quarterly interim dividend held consistent at 7.5 cents per share also leads to lesser attractiveness in terms of yield (c.3.4%).

 

 

Latest Reports

Join Events & Seminars

Learn best practices and latest market outlook from experts and special guests

Hear & Ask our Experts

Join live weekly market calls

Read Popular News & Reports, Technical Pulses

at www.stocksbnb.com

Subscribe to our YouTube Channel

New video every week

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com